Editor’s note: Pancreatic Cancer Action Network (PanCAN) President and CEO Julie Fleshman attended the Harvard Business School (HBS) Kraft Precision […]
Precision Promise is the first adaptive clinical trial platform for pancreatic cancer patients in the world and the Pancreatic Cancer Action Network’s groundbreaking initiative to dramatically improve patient outcomes and advance the organization’s goal to double survival by 2020.
Designed with a nationwide team of leading clinicians, researchers and diagnostic and drug developers, Precision Promise will continuously and rapidly bring new treatment options to patients and transform the future of clinical research.
Precision Promise will learn faster by requiring fewer patients to more rapidly answer important scientific questions for a disease where there is no time to waste.
The Pancreatic Cancer Action Network serves as the trusted and unbiased facilitator that brings together key stakeholders to make this historic initiative possible.
Every single patient treated at our Clinical Trial Consortium sites will receive best-in-class supportive care alongside treatment.
When will Precision Promise launch?
We are excited to launch Precision Promise in the second half of 2018. It’s a top priority for PanCAN and a key part of our comprehensive strategy to improve outcomes for pancreatic cancer patients. We are making progress every day and this timeline ensures that Precision Promise is sustainable and robust in advancing novel treatments for all those facing pancreatic cancer.
Patients who have been diagnosed with pancreatic cancer should not delay treatments. If you are diagnosed with pancreatic cancer, please contact Patient Central to learn about potential clinical trial options that are available to you now.
Why Precision Promise?
Pancreatic cancer is the world’s toughest cancer with a five-year survival rate of just 9 percent and the third leading cause of cancer-related death in the United States. Nationally only 4 percent of pancreatic cancer patients enroll in clinical trials.
To change the pancreatic cancer treatment paradigm, Precision Promise will simultaneously test multiple leading-edge therapeutic options at the same time, compared to traditional trials that test only one or two treatments at the same time.
Who is Involved in Precision Promise?
The Pancreatic Cancer Action Network has created an unprecedented model of cooperation, led by a steering committee and sub-committees of renowned experts from across the nation.
Precision Promise’s initial Clinical Trial Consortium sites were selected through a competitive peer-review process and include premier cancer treatment institutions across the country. Starting in 2018, patients will be able to enroll in Precision Promise through the Clinical Trial Consortium sites.
We’ve teamed up with leading statistical and clinical trial design experts, Berry Consultants, to develop and implement Precision Promise’s sophisticated adaptive design. Working with Berry Consultants’ statistical and clinical trial strategy teams, Precision Promise will truly be on the leading-edge of science and medicine -- accelerating learning and progress for patients.
Precision Promise will partner with health-tech company, Tempus, to utilize their cutting-edge genomic sequencing and analysis methods.
What is the difference between Precision Promise and other clinical trials?
The Precision Promise adaptive randomized clinical trial platform allows multiple novel therapies to be evaluated alongside standard of care approaches to provide the opportunity to get new treatments rapidly and efficiently approved for pancreatic cancer.
A unique aspect of Precision Promise is that, in one clinical trial setting, a patient has the opportunity for a second treatment when if the first treatment is no longer working. This has never been done before in a clinical trial setting.
Through Precision Promise, clinical, correlative and outcomes data will be continuously tracked and analyzed together across the Clinical Trial Consortium sites so that scientific findings can be determined efficiently and disseminated in a timely manner.
What treatment options will be included in Precision Promise?
Based on the most promising science available, Precision Promise will initially tackle pancreatic cancer from a few key angles, including immunotherapy, stroma disruption and DNA damage repair defects.
As we learn what works best, the treatment options will change and grow, with new promising therapeutic options added as they emerge.
How can I support Precision Promise?
We will only be able to realize the full potential of Precision Promise with the support of generous individuals who understand the power of extraordinary collaboration to transform outcomes for patients facing pancreatic cancer. Please join us by making a gift today.
Join us to revolutionize the future of pancreatic cancer.
Other Relevant Topics:
- Precision Promise leadership team
- Precision Promise initial Clinical Trial Consortium
- Learn more about Patient Services